Meridia News|Truly global news from every meridian
Brazil·Agencia Brasil·Portuguese
·health

Injectable medication that prevents HIV may enter the SUS by the end of the year

The Unified Health System (SUS) may begin offering this year a new form of pre-exposure prophylaxis (PrEP), applied by injection, for HIV prevention. This is the medication cabotegravir, which prevents virus replication over a prolonged period and can be taken every two months. The request for inclusion will be sent by the Ministry of Health to the National Commission for the Incorporation of New Technologies in the SUS (Conitec) next week. Conitec is an independent committee that needs to evaluate aspects such as the cost-benefit of offering new treatments through public services, before they are included in the SUS portfolio. Related news: HIV infections and deaths decline, but lack of resources threatens progress. Research points to gap between knowledge and use of PrEP against HIV. The commission may recommend or not the inclusion, but the final decision is up to the Ministry. According to Health Minister Alexandre Padilha, the government is still negotiating with the pharmaceutical

Read original at Agencia Brasil →
Injectable medication that prevents HIV may enter the SUS by the end of the year
© Fernando Frazão/Agência Brasil

Brazil's Public Health System May Offer Injected HIV Prevention This Year

Brazil's Unified Health System (SUS) may begin offering a new form of injectable pre-exposure prophylaxis (PrEP) for HIV prevention as early as this year. The medication is cabotegravir, which prevents the virus from replicating over an extended period and can be administered every two months.

The Ministry of Health will submit a request for inclusion to the National Commission for Incorporation of New Technologies in the SUS (Conitec) next week. Conitec is an independent committee that must evaluate aspects such as the cost-benefit of offering new treatments through public services before they are added to the SUS formulary.

The commission may recommend or reject inclusion, but the final decision rests with the Ministry. According to Health Minister Alexandre Padilha, the government is still negotiating with pharmaceutical company GSK, the producer of cabotegravir, over the final cost of the medication and how many doses will be purchased, but the company has made an offer with an "adequate price."

"We see new extended-protection technologies with great hope, but we demand that they be offered, especially to our national health systems, at adequate prices, not stratospheric prices," the minister said at a press conference before the opening of the 26th International AIDS Conference in Rio de Janeiro.

Lenacapavir

According to Padilha, cost was the determining factor in the government's choice of the injectable PrEP it plans to offer. Another medication, called lenacapavir, provides even longer protection—for six months—but was offered at an unfeasible price, the minister said.

"Even with Brazil willing to pay up to 10 times the amount that was offered to countries similar to ours, such as Indonesia and Thailand, the industry still said it cannot offer it to the national public system at that price. So we will not pay. We will not drain the resources from Brazilian taxpayers' taxes for the profit interest of a company."

Despite being one of the countries where the medication was tested, Brazil was excluded from the voluntary licensing agreement signed by pharmaceutical company Gilead, which authorized six companies to produce generic versions of lenacapavir for distribution in 120 countries.

The measure was criticized by other participants at the Conference, including the Joint United Nations Programme on HIV/AIDS (UNAIDS), because lenacapavir is considered central to ending the AIDS epidemic, and organizations involved in the issue argue that access to the medication should be expanded worldwide.

The pharmaceutical company stated in a note that it shares the urgency of expanding access to lenacapavir throughout Latin America and the Caribbean, but that "for countries outside the voluntary licensing territory, such as Brazil, it continues to seek sustainable long-term access pathways, aligned with local market conditions and public health priorities."

According to the note released by Gilead after statements made at the event, "Brazil is one of the priorities among countries evaluated as potential manufacturing partners." For this reason, the pharmaceutical company signed a memorandum of understanding with the Oswaldo Cruz Foundation "to explore potential opportunities for technology transfer that could support access in Brazil and throughout the region."

Oral PrEP

The Unified Health System already offers PrEP, but in oral form, as tablets that must be taken daily. More than 350,000 people have already had access to the medication, which also has proven efficacy.

The main advantage of injectable PrEP over the oral version is treatment adherence, since the tablets must be taken every day to ensure their effect. A Fiocruz study conducted with 1,400 people in six Brazilian cities showed that 83 percent preferred the injection.

In addition, 94 percent of participants came to the health service to receive injections on schedule, which ensured they remained protected throughout treatment. None of them were infected with the virus.

Another real-world study released by pharmaceutical companies ViiV Healthcare and GSK, which developed the medication, demonstrated high efficacy, with an annual HIV infection rate of only 0.1 percent.

Agência Brasil

About this translation

This article was translated from Portuguese into English by Meridia News using AI, and may contain errors. How Meridia translates

Original headline
Remédio injetável que previne HIV pode entrar no SUS até o fim o ano
Published by
Agencia Brasil,
Original article
Read at Agencia Brasil ↗